Onasemnogene Abeparvovec-Xioi
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 172 publications
P5 promoter-mediated incorporation explains REP/CAP manufacturing contaminants in patient liver after rAAV gene therapy.
Journal: medRxiv : the preprint server for health sciences
Published: September 24, 2026
Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease.
Journal: Expert reviews in molecular medicine
Published: September 23, 2026
Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland - part II - expert based recommendations for surveillance and management of side-effects.
Journal: Journal of neuromuscular diseases
Published: August 27, 2026
289th ENMC international workshop: assessing and managing emerging AAV related toxicities after gene therapy for neuromuscular disorders, 26 - 28 September 2025, Hoofddorp, The Netherlands.
Journal: Neuromuscular disorders : NMD
Published: July 10, 2026
The role of vascular pathology in SMA: implications for pathogenesis and treatment.
Journal: Frontiers in cellular neuroscience
Published: July 09, 2026
External controls for rare disease drug development: Lessons for emerging and advanced therapeutic modalities.
Journal: Molecular therapy. Advances
Published: May 29, 2026
Trends in the Engineering of Adeno-Associated Virus (AAV) for Precision Gene Delivery to the Central Nervous System (CNS).
Journal: International journal of molecular sciences
Published: May 07, 2026
Adeno-Associated Virus Gene Delivery to Hard-to-Transduce Tissues: Biological Barriers, Engineering Strategies, and Clinical Challenges.
Journal: Human gene therapy
Published: April 04, 2026
CRISPR-Cas editing technologies for viral-mediated gene therapies of human diseases: Mechanisms, progress, and challenges.
Journal: Molecular therapy. Nucleic acids
Published: January 07, 2026
Summary of Research: Risdiplam Treatment Following Onasemnogene Abeparvovec in Individuals with Spinal Muscular Atrophy: A Multicenter Case Series.
Journal: Advances in therapy
Published: December 12, 2025
Onasemnogene Abeparvovec in Patients With SMA: Interim Results of the RESTORE Registry in Japan.
Journal: Annals of clinical and translational neurology
Published: December 04, 2025
Last Updated: 11/08/2026